(COO) The Cooper Companies - Ratings and Ratios
Contact Lenses, Fertility Products, Surgical Devices, Contraception, Cryostorage
COO EPS (Earnings per Share)
COO Revenue
Description: COO The Cooper Companies
The Cooper Companies, Inc. (COO) is a healthcare company with a diversified portfolio of products and services across two main segments: CooperVision and CooperSurgical. CooperVision is a leading manufacturer of contact lenses, offering a range of products that cater to various vision correction needs, including astigmatism, presbyopia, and myopia. The segment has a strong global presence, with products sold in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
CooperSurgical, on the other hand, focuses on family and womens healthcare, providing a range of products and services, including fertility treatments, medical devices, and contraception. The segment also offers cryostorage services, such as cord blood and cord tissue storage, to healthcare professionals and patients worldwide. With a broad customer base that includes distributors, group purchasing organizations, eye care and healthcare professionals, and authorized resellers, COO has a robust distribution network.
From a financial perspective, COOs revenue growth is driven by the demand for its contact lenses and womens healthcare products. Key performance indicators (KPIs) to watch include revenue growth rate, gross margin, and operating expenses as a percentage of revenue. The companys return on equity (ROE) is relatively low at 5.11%, indicating potential for improvement in profitability. Additionally, the price-to-earnings (P/E) ratio of 35.86 suggests that the stock may be overvalued, while the forward P/E ratio of 16.95 indicates expected earnings growth.
To further evaluate COOs performance, its essential to analyze its operating metrics, such as the number of contact lenses sold, market share in the contact lens market, and the growth rate of its CooperSurgical segment. Other relevant KPIs include the companys research and development (R&D) expenses as a percentage of revenue, indicating its commitment to innovation, and its debt-to-equity ratio, which can impact its financial flexibility and ability to invest in growth opportunities.
COO Stock Overview
| Market Cap in USD | 13,676m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 1983-12-30 |
COO Stock Ratings
| Growth Rating | -50.3% |
| Fundamental | 57.2% |
| Dividend Rating | 1.21% |
| Return 12m vs S&P 500 | -50.7% |
| Analyst Rating | 4.05 of 5 |
COO Dividends
Currently no dividends paidCOO Growth Ratios
| Growth Correlation 3m | -30.8% |
| Growth Correlation 12m | -95.1% |
| Growth Correlation 5y | -25.7% |
| CAGR 5y | -2.79% |
| CAGR/Max DD 3y | -0.07 |
| CAGR/Mean DD 3y | -0.34 |
| Sharpe Ratio 12m | -0.22 |
| Alpha | 0.00 |
| Beta | 0.979 |
| Volatility | 43.22% |
| Current Volume | 1865.8k |
| Average Volume 20d | 2923.6k |
| Stop Loss | 62.7 (-3.8%) |
| Signal | -0.95 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (407.8m TTM) > 0 and > 6% of Revenue (6% = 242.7m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 1.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 27.87% (prev 25.16%; Δ 2.71pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 816.3m > Net Income 407.8m (YES >=105%, WARN >=100%) |
| Net Debt (2.35b) to EBITDA (1.09b) ratio: 2.16 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (200.6m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 66.96% (prev 66.36%; Δ 0.60pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.05% (prev 31.42%; Δ 1.63pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.45 (EBITDA TTM 1.09b / Interest Expense TTM 111.7m) >= 6 (WARN >= 3) |
Altman Z'' 4.86
| (A) 0.09 = (Total Current Assets 2.14b - Total Current Liabilities 1.01b) / Total Assets 12.38b |
| (B) 0.61 = Retained Earnings (Balance) 7.56b / Total Assets 12.38b |
| (C) 0.06 = EBIT TTM 720.9m / Avg Total Assets 12.24b |
| (D) 1.79 = Book Value of Equity 7.19b / Total Liabilities 4.02b |
| Total Rating: 4.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 57.16
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 2.57% = 1.28 |
| 3. FCF Margin 10.18% = 2.55 |
| 4. Debt/Equity 0.30 = 2.46 |
| 5. Debt/Ebitda 2.27 = -0.53 |
| 6. ROIC - WACC -3.74% = -4.67 |
| 7. RoE 4.97% = 0.41 |
| 8. Rev. Trend 94.24% = 7.07 |
| 9. EPS Trend -78.24% = -3.91 |
What is the price of COO shares?
Over the past week, the price has changed by -4.53%, over one month by -11.38%, over three months by -6.57% and over the past year by -41.42%.
Is The Cooper Companies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of COO is around 53.62 USD . This means that COO is currently overvalued and has a potential downside of -17.71%.
Is COO a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 8
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the COO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 84.5 | 29.6% |
| Analysts Target Price | 84.5 | 29.6% |
| ValueRay Target Price | 59.7 | -8.5% |
Last update: 2025-09-10 02:43
COO Fundamental Data Overview
CCE Cash And Equivalents = 124.9m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 33.7206
P/E Forward = 15.528
P/S = 3.3804
P/B = 1.6206
P/EG = 1.0935
Beta = 0.974
Revenue TTM = 4.05b USD
EBIT TTM = 720.9m USD
EBITDA TTM = 1.09b USD
Long Term Debt = 2.43b USD (from longTermDebt, last quarter)
Short Term Debt = 47.8m USD (from shortTermDebt, last quarter)
Debt = 2.48b USD (Calculated: Short Term 47.8m + Long Term 2.43b)
Net Debt = 2.35b USD (from netDebt column, last quarter)
Enterprise Value = 16.03b USD (13.68b + Debt 2.48b - CCE 124.9m)
Interest Coverage Ratio = 6.45 (Ebit TTM 720.9m / Interest Expense TTM 111.7m)
FCF Yield = 2.57% (FCF TTM 411.9m / Enterprise Value 16.03b)
FCF Margin = 10.18% (FCF TTM 411.9m / Revenue TTM 4.05b)
Net Margin = 10.08% (Net Income TTM 407.8m / Revenue TTM 4.05b)
Gross Margin = 66.96% ((Revenue TTM 4.05b - Cost of Revenue TTM 1.34b) / Revenue TTM)
Tobins Q-Ratio = 2.23 (Enterprise Value 16.03b / Book Value Of Equity 7.19b)
Interest Expense / Debt = 1.03% (Interest Expense 25.4m / Debt 2.48b)
Taxrate = 32.63% (190.0m / 582.3m)
NOPAT = 485.7m (EBIT 720.9m * (1 - 32.63%))
Current Ratio = 2.12 (Total Current Assets 2.14b / Total Current Liabilities 1.01b)
Debt / Equity = 0.30 (Debt 2.48b / last Quarter total Stockholder Equity 8.35b)
Debt / EBITDA = 2.27 (Net Debt 2.35b / EBITDA 1.09b)
Debt / FCF = 6.01 (Debt 2.48b / FCF TTM 411.9m)
Total Stockholder Equity = 8.21b (last 4 quarters mean)
RoA = 3.29% (Net Income 407.8m, Total Assets 12.38b )
RoE = 4.97% (Net Income TTM 407.8m / Total Stockholder Equity 8.21b)
RoCE = 6.77% (Ebit 720.9m / (Equity 8.21b + L.T.Debt 2.43b))
RoIC = 4.52% (NOPAT 485.7m / Invested Capital 10.76b)
WACC = 8.25% (E(13.68b)/V(16.15b) * Re(9.62%)) + (D(2.48b)/V(16.15b) * Rd(1.03%) * (1-Tc(0.33)))
Shares Correlation 3-Years: 83.09 | Cagr: 0.10%
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 69.79% ; FCFE base≈322.8m ; Y1≈276.2m ; Y5≈214.6m
Fair Price DCF = 15.20 (DCF Value 3.02b / Shares Outstanding 198.8m; 5y FCF grow -17.55% → 3.0% )
EPS Correlation: -78.24 | EPS CAGR: -28.34% | SUE: 1.18 | # QB: 2
Revenue Correlation: 94.24 | Revenue CAGR: 8.46%
Additional Sources for COO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle